Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.5
5.2
Journals
Cells
Special Issues
New Advances in Tissue Engineering and Regeneration
share announcement

New Advances in Tissue Engineering and Regeneration

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Tissues and Organs".

Deadline for manuscript submissions: 25 January 2027 | Viewed by 3400

Special Issue Editors

Dr. Giorgia Borciani

E-Mail
Guest Editor
RAMSES Laboratory for Personalized Regenerative Medicine for the Musculoskeletal System, Rizzoli Orthopedic Institute, Bologna, Italy
Interests: regenerative medicine; bone tissue regeneration; cartilage regeneration; biomaterials for tissue engineering; osteoporosis
Dr. Giorgia Montalbano

E-Mail Website
Guest Editor
Department of Applied Science and Technology, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Torino, Italy
Interests: bone tissue engineering; 3D printed scaffolds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Tissue engineering and regenerative medicine represent rapidly advancing fields of biomedical research, aiming to restore, replace, or enhance the function of damaged or diseased tissues.

These interdisciplinary fields combine principles from cell biology, materials science, and bioengineering to develop biologically functional constructs through the combination of scaffolds, cells, and bioactive molecules.

Recent advances have significantly expanded the therapeutic potential of engineered tissues and organoids, such as the use of stem cells, bioactive biomaterials, and bioprinting technologies.

This Special Issue has the intention to highlight the latest innovations, interdisciplinary strategies, and translational efforts in tissue engineering and regeneration, with the final goal of addressing unmet medical needs, focusing on the concept of “from bench to bedside”.

We invite contributions that explore novel biomaterials, advanced fabrication techniques, cell-based therapies that aim to propose solutions for tissue repair and organ regeneration.

We encourage original research articles and reviews that reflect cutting-edge science and technology, with the final goal of accelerating the progress toward effective regenerative therapies.

Dr. Giorgia Borciani
Dr. Giorgia Montalbano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tissue regeneration
  • tissue engineering
  • regenerative medicine
  • musculoskeletal tissues
  • biomaterials
  • stem cells
  • 3D bioprinting
  • scaffold design
  • cell therapy
  • organoids
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

27 pages, 8516 KB  
Article
Cell Supported Single Membrane Technique for the Treatment of Large Bone Defects: Depletion of CD8+ Cells Enhances Bone Healing Mechanisms During the Early Bone Healing Phase
by Marissa Penna-Martinez, Lia Klausner, Andreas Kammerer, Minhong Wang, Alexander Schaible, René Danilo Verboket, Christoph Nau, Ingo Marzi and Dirk Henrich
Cells 2026, 15(3), 215; https://doi.org/10.3390/cells15030215 - 23 Jan 2026
Abstract
Introduction: The one-step membrane technique, derived from the Masquelet induced membrane technique, uses human acellular dermal matrix (hADM) that is wrapped around the bone defect to bypass membrane induction, reducing treatment time. Pre-colonization of hADM with bone marrow cells (BMC), particularly after CD8 [...] Read more.
Introduction: The one-step membrane technique, derived from the Masquelet induced membrane technique, uses human acellular dermal matrix (hADM) that is wrapped around the bone defect to bypass membrane induction, reducing treatment time. Pre-colonization of hADM with bone marrow cells (BMC), particularly after CD8+ T cell depletion, enhances bone regeneration. This study examined how CD8+ T cell depletion alters the proteins accumulated in the hADM during early healing. Materials and Methods: Eighteen male Sprague-Dawley rats received 5 mm femoral defects filled with autologous bone chips and wrapped with hADM, hADM + BMC, or hADM + BMC-CD8. hADMs were recovered on days 3 and 7 (n = 3/group/timepoint), incubated ex vivo, and conditioned medium analyzed with a proteome profiler detecting 79 proteins. Results: The protein content of the hADM evolved dynamically. At day three, 41 proteins were detected, rising to 47 by day seven, with RGM-A, osteoprotegerin, LIF, IL-6, CCL20, and CCL17 emerging late, consistent with increased regenerative activity. CD8+ T cell depletion suppressed early inflammatory and pro-osteogenic mediators (e.g., CCL2, IGF-I, IL-1RA) while upregulating LIX. By day seven, regenerative mediators (CCL20, GDF-15, RGM-A) were enriched, whereas inflammatory factors (CCL21, IL-1a, WISP-1) declined. MMP-9, Galectin-1, and GDF-15 increased exclusively in the CD8-depleted group. Conclusions: The hADM protein content transitions from pro-inflammatory to pro-regenerative within one week after surgery. CD8+ T cell depletion accelerates this shift, highlighting hADM as a dynamic scaffold that contributes to the immune–regenerative crosstalk in bone healing. Full article
(This article belongs to the Special Issue New Advances in Tissue Engineering and Regeneration)
24 pages, 9909 KB  
Article
Differential Immune Response to Hydroxyapatite Precursors Under Inflammatory Pressure: In Vitro and In Vivo Studies
by Irina S. Fadeeva, Anastasia Yu. Teterina, Igor V. Smirnov, Vladislav V. Minaychev, Mikhail A. Shlykov, Margarita I. Kobyakova, Polina V. Smirnova, Anatoliy S. Senotov, Alena I. Zvyagina, Viktor A. Palikov, Arina V. Kholina, Eugeny S. Mikhaylov, Roman S. Fadeev and Vladimir S. Komlev
Cells 2026, 15(2), 101; https://doi.org/10.3390/cells15020101 - 6 Jan 2026
Viewed by 218
Abstract
The clinical success of calcium phosphate bone grafts (CPs) largely depends on the body’s immune response. However, traditional biocompatibility tests use healthy organisms and cannot predict effectiveness in patients with common chronic inflammatory diseases. This study examines how inflammation modulates the immune response, [...] Read more.
The clinical success of calcium phosphate bone grafts (CPs) largely depends on the body’s immune response. However, traditional biocompatibility tests use healthy organisms and cannot predict effectiveness in patients with common chronic inflammatory diseases. This study examines how inflammation modulates the immune response, in vitro and in vivo, to low-temperature biomimetic CPs: dicalcium phosphate dihydrate (DCPD), octacalcium phosphate (OCP), and hydroxyapatite (HAp). In vitro studies involved human monocytes, macrophages, lymphocytes, and mesenchymal stromal cells (MSCs), with or without pro-inflammatory activation. In vivo biocompatibility was assessed via subcutaneous implantation in rats, with or without Complete Freund’s Adjuvant (CFA)-induced inflammation. Under normal conditions, all CP caused minimal immune reactivity. Inflammation-activated macrophages, however, triggered an acute reaction with significantly increased TNF-α and IL-1β secretion. Healthy and inflamed animals showed sharp contrasts. Although all materials exhibited thickened fibrous capsules during inflammation, biocompatibility varied markedly: DCPD performed best by promoting angiogenesis with minimal inflammation; HAp provoked the most severes response, including tissue necrosis and signs of rejection; OCP showed intermediate effects, with angiogenesis but notable fibrosis. Inflammatory processes critically influence CP biocompatibility; materials biocompatible in healthy organisms can induce fibrosis or rejection under inflammation. Disease-relevant, immune-challenged models are essential to predict clinical efficacy and safety. Full article
(This article belongs to the Special Issue New Advances in Tissue Engineering and Regeneration)
►▼ Show Figures

Figure 1

19 pages, 6972 KB  
Article
Development and Characterization of a Novel Lineage of Renal Progenitor Cells for Potential Use in Feline Chronic Kidney Disease: A Preliminary Study
by Lara Carolina Mario, Juliana de Paula Nhanharelli, Jéssica Borghesi, Rafaela Rodrigues Ribeiro, Hianka Jasmyne Costa de Carvalho, Thamires Santos da Silva, Mariano del Sol, Rodrigo da Silva Nunes Barreto, Sandra Maria Barbalho and Maria Angelica Miglino
Cells 2025, 14(17), 1395; https://doi.org/10.3390/cells14171395 - 6 Sep 2025
Viewed by 1929
Abstract
Chronic kidney disease (CKD) is a common and serious condition in felines. Accordingly, several cell therapies have been studied over the past decades for effective treatments. This study aimed to develop a new lineage of renal progenitor cells for use in cats with [...] Read more.
Chronic kidney disease (CKD) is a common and serious condition in felines. Accordingly, several cell therapies have been studied over the past decades for effective treatments. This study aimed to develop a new lineage of renal progenitor cells for use in cats with CKD. Metanephric and mesonephric progenitor cells were obtained from mesonephros and metanephros tissues of feline conceptuses at four distinct gestational stages. The cultured cells were characterized by their morphology, tumorigenic potential, immunophenotype determined by flow cytometry, and differentiation potential. We then conducted a pilot study in CKD-affected cats, comparing intraperitoneal injections of cultured metanephric progenitor cells (n = 4) to a placebo solution (n = 3). All four cell types exhibited adhesion and colony formation, but showed no tumorigenic potential. Cells tested positive for renal progenitor markers (CD117, Nephron, and WT1), confirming their identity. Treated cats showed no statistically significant differences (p ≤ 0.05) in any of the data analyzed. However, caregivers reported a voluntary increase in appetite after cell administration. Veterinarians confirmed this information during double-blind evaluations conducted after treatment. Although this data are qualitative, no clinical deterioration was observed in cats. Our results suggest that this new lineage of renal progenitor cells did not induce immediate adverse effects, thus supporting its potential for use in cell-based therapies. However, further studies are needed to evaluate its efficacy in treating renal diseases. Full article
(This article belongs to the Special Issue New Advances in Tissue Engineering and Regeneration)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop